← Back to Screener
Neogen Corp (NEOG)
Price$9.63
Favorite Metrics
Price vs S&P 500 (26W)48.70%
Price vs S&P 500 (4W)4.26%
Market Capitalization$2.08B
All Metrics
P/CF (Annual)35.71x
Book Value / Share (Quarterly)$9.66
P/TBV (Annual)1.87x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)19.28%
Cash Flow / Share (Quarterly)$0.03
Price vs S&P 500 (YTD)31.91%
Gross Margin (TTM)45.20%
Net Profit Margin (TTM)-69.93%
EPS (TTM)$-2.80
10-Day Avg Trading Volume3.32M
EPS Excl Extra (TTM)$-2.80
Revenue Growth (5Y)16.43%
EPS (Annual)$-5.03
ROI (Annual)-36.83%
Gross Margin (Annual)47.10%
Net Profit Margin (5Y Avg)-20.74%
Cash / Share (Quarterly)$0.73
Revenue Growth QoQ (YoY)-4.43%
ROA (Last FY)-31.71%
Revenue Growth TTM (YoY)-3.91%
EBITD / Share (TTM)$-2.14
ROE (5Y Avg)-8.21%
Operating Margin (TTM)-64.28%
Cash Flow / Share (Annual)$-0.21
P/B Ratio0.99x
P/B Ratio (Quarterly)1.15x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)3.12x
Net Interest Coverage (TTM)-14.69x
ROA (TTM)-17.98%
EV / EBITDA (TTM)17.77x
EPS Incl Extra (Annual)$-5.03
Current Ratio (Annual)3.32x
Quick Ratio (Quarterly)2.42x
3-Month Avg Trading Volume3.41M
52-Week Price Return106.74%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.49
P/S Ratio (Annual)2.32x
Asset Turnover (Annual)0.26x
52-Week High$11.43
Operating Margin (5Y Avg)-16.14%
EPS Excl Extra (Annual)$-5.03
CapEx CAGR (5Y)34.18%
Tangible BV CAGR (5Y)0.07%
26-Week Price Return57.45%
Quick Ratio (Annual)1.91x
13-Week Price Return1.28%
Total Debt / Equity (Annual)0.43x
Current Ratio (Quarterly)3.92x
Enterprise Value$2,713.266
Revenue / Share Growth (5Y)0.84%
Asset Turnover (TTM)0.26x
Book Value / Share Growth (5Y)6.90%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.49x
Pretax Margin (Annual)-126.65%
Cash / Share (Annual)$0.60
3-Month Return Std Dev44.15%
Gross Margin (5Y Avg)47.73%
Net Income / Employee (TTM)$-0
EBITDA Interim CAGR (5Y)-5.17%
ROE (Last FY)-52.72%
Net Interest Coverage (Annual)-8.83x
EPS Basic Excl Extra (Annual)$-5.03
P/FCF (TTM)108.02x
Receivables Turnover (TTM)5.86x
EV / Free Cash Flow (TTM)444.36x
Total Debt / Equity (Quarterly)0.38x
EPS Incl Extra (TTM)$-2.80
Receivables Turnover (Annual)5.48x
ROI (TTM)-20.87%
P/S Ratio (TTM)2.39x
Pretax Margin (5Y Avg)-20.68%
Revenue / Share (Annual)$4.12
Tangible BV / Share (Annual)$3.05
Forward P/E26.94x
Price vs S&P 500 (52W)71.64%
Year-to-Date Return36.05%
5-Day Price Return4.05%
EPS Normalized (Annual)$-5.03
ROA (5Y Avg)-4.19%
Net Profit Margin (Annual)-122.06%
Month-to-Date Return2.37%
Cash Flow / Share (TTM)$0.39
EBITD / Share (Annual)$-4.34
Operating Margin (Annual)-118.59%
LT Debt / Equity (Annual)0.42x
P/CF (TTM)29.91x
ROI (5Y Avg)-4.99%
LT Debt / Equity (Quarterly)0.38x
EPS Basic Excl Extra (TTM)$-2.80
P/TBV (Quarterly)3.19x
P/B Ratio (Annual)0.60x
Inventory Turnover (TTM)2.60x
Pretax Margin (TTM)-72.15%
Book Value / Share (Annual)$9.56
Price vs S&P 500 (13W)-1.59%
Beta1.89x
P/FCF (Annual)47.69x
Revenue / Share (TTM)$4.00
ROE (TTM)-29.00%
52-Week Low$4.32
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.91
3.91
3.91
3.91
Industry Peers — In Vitro Diagnostics(17)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NEOGNeogen Corp | 2.39x | -3.91% | 45.20% | — | $9.63 |
IDXXIdexx Laboratories Inc | 10.72x | 10.42% | 61.80% | 14.28% | $583.06 |
LNTHLantheus Holdings, Inc | 3.55x | 0.50% | 61.10% | 40.71% | $83.97 |
NNNNAnbio Biotechnology Class A Ordinary Shares | 295.25x | -5.72% | 89.00% | — | $26.98 |
CLDXCelldex Therapeutics, Inc | 1753.49x | -77.98% | 17.65% | — | $34.38 |
NTLAIntellia Therapeutics, Inc | 26.55x | 16.92% | — | — | $15.21 |
QDELQuidelOrtho Corporation Common Stock | 0.32x | -1.89% | 46.67% | — | $12.89 |
MYGNMyriad Genetics Inc | 0.59x | -1.56% | 69.93% | — | $5.14 |
ACHVAchieve Life Sciences, Inc. | 12.70x | -89.25% | — | — | $4.25 |
TKNOAlpha Teknova, Inc. Common Stock | 3.87x | 7.35% | 33.17% | — | $2.91 |
IMDXInsight Molecular Diagnostics Inc. Common Stock | 31.65x | 115.58% | 56.97% | — | $3.99 |
About
Neogen Corporation develops food and animal safety solutions, offering diagnostics to detect pathogens, toxins, allergens, and contaminants in food and animal feed. The company operates through two segments: food safety diagnostics and animal health products, which include veterinary pharmaceuticals, vaccines, instruments, and genomics testing services. Based in Lansing, Michigan, Neogen serves food processors and agricultural businesses seeking to ensure product safety and traceability.